Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience

Little is known about how the change from intravenous to subcutaneous vedolizumab in a real-life setting in inflammatory bowel disease patients on stable maintenance therapy affects clinical outcomes. We compared the data on vedolizumab serum trough concentration, efficacy, and safety prior to and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Oršić Frič, Vlasta, Borzan, Vladimir, Šahinović, Ines, Borzan, Andrej, Kurbel, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962491/
https://www.ncbi.nlm.nih.gov/pubmed/37259387
http://dx.doi.org/10.3390/ph16020239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962491/
https://www.ncbi.nlm.nih.gov/pubmed/37259387
http://dx.doi.org/10.3390/ph16020239

Ejemplares similares